If we have a case, it certainly isn't based on this:
"As
If we have a case, it certainly isn't based on this:
"As Sichenzia is no doubt aware, Mr. Kahlon has been sued by the SEC for practicing the business model that he taught to Mr. Sason."
Kahlon was in trouble with the SEC because he sold shares that weren't registered. Magna isn't doing the same thing remotely.
The shares Magna are selling are registered and the terms of the deal are fully disclosed.
The Kahlon stuff is fluff as it relates to AMBS. Similar to the description of penny stocks and wildcatters.
If we have a case, it will be based on other illegal activities - illegal shorting, violations of terms of leak out agreement, conspiracy with offshore funds, etc.
That is the missing piece. You can't just say they are violating the securities laws. You have to point to where they are.
The beauty of Magna (and payday loans) is that they don't violate the law. The law should be changed to ban toxic financing like this but, as of right now, it is not illegal in and of itself.
1
Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Actinium Pharmaceuticals Steps into the Spotlight Alright, folks, here we have Actinium Pharmaceuticals, Inc. gearing up to make some noise at the H.C. Wainwright 28th Annual Global Investment Conference. This isn't just any roadshow—it's a chance to showcase the kind of pioneering work they're doing in targeted radiotherapies. With Sandesh Seth, the Chairman, taking...
Continue Reading
Why Laughing Gas is a Game-Changer in Pediatric Dentistry You ever seen a kid freeze up like a deer in headlights at the dentist's office? I'm telling you, it's not just the sweet tooth nightmare but often the fear of that cold, intimidating chair. But let's talk about a game-changer: laughing gas or, known in the trade as nitrous oxide. Keeping Anxiety at Bay: The Role...
Continue Reading
Breathing New Life into Clinical Trials Alright, folks, listen up. We've got a fresh collaboration cooking that could shake things up in the clinical trial sector. Signant Health, a heavyweight in clinical trial solutions, has teamed up with Lothar Medical, and they’ve hitched their wagons to launch something rather intriguing: the ALDS PRO pulmonary function tech. Let...
Continue Reading
Pushing Forward Yet Stumbling on the Details We've got a fresh scoop from the AI Leaders Council: They just rolled out their 2026 Corporate AI Talent Study. What's the big fuss? Well, they're tracking how companies are cozying up to artificial intelligence. Let's just say it's a mixed bag this time around. While almost everyone jumped on the AI bandwagon, only a scant 3%...
Continue Reading
Why Virterion Stands Out in 2026 VPS Landscape For anyone knee-deep in the hosting game, you know the market's got more players than a late-night poker round. Virterion, though—that's a name carving out a noticeable niche, and for solid reasons. In 2026, the backdrop's not just speed, it’s about matching technology and support with what ambitious developers need. VPS...
Continue Reading
Cooking Up High Margins and Rapid Growth You don’t stumble on opportunities like this every day. A foodservice company out there is posting some mouth-watering numbers, and it’s shaking up the M&A scene. This one’s got patents holding up its brand like a culinary force field, and it’s now on the auction block for a cool $1.6 million. And the numbers? Well, they...
Continue Reading
Shifting Gears at the Checkout Counter Let's face it, we've all been there: you click, you pay, and then you wait. But what happens next is where brands often drop the ball. Sure, e-commerce has been all about getting us to trust the 'buy' button. That's where folks like XCOTTON are stepping up to the plate, giving us something else to consider. They were loud and clear...
Continue Reading
Overnight Sensation or Future Staple? I wonder if Dreame's top brass woke up sweating or smiling after their big reveal at IFA 2026. A buffet of over 100 products across 16 categories is no small feat, especially when you're banking on technologies developed over nine years. But let's cut through the noise—does this showcase promise innovation or just smoke and mirrors?...
Continue Reading
Wrapping Up a Wild Ride in the Investment Arena Markets are a fickle friend, and today we've got Inturai Ventures calling it a day on their latest cash grab. They've locked the final tranche of their private placement, pulling in an aggregate $963,713.70. Feels like they're counting pennies in this venture, but every cent counts when your aim is to shake up industries...
Continue Reading
Legal Storm Brewing with AEVEX's IPO Disclosures Whatever happened to straightforward honesty in business? AEVEX Corp. (NYSE: AVEX) might have forgotten that chapter judging by fresh allegations in their midst. Investors who bought AVEX Class A common stock between April 17 and June 4, 2026, have been hit with a curveball: a looming class action lawsuit for securities...
Continue Reading
ing Brands Faces Legal Probe; Fiduciary Duties Questioned">
Continue Reading